secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cyclerion Therapeutics, Inc. (CYCN)
CIK:        0001755237
Form:       8-K
Filed at:   2025-12-01T23:59:59+00:00
Accession:  0001193125-25-304067
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclerion to receive $1M milestone if Akebia doses first patient in Phase 2 FSGS trial
--------------------------------------------------------------------------------

- Akebia announced Phase 2 trial initiation for Praliciguat in FSGS; first patient dosing expected in 2026.
- Under license amendment, Cyclerion is owed $1.0M upon first patient dosed in a US Phase 2 trial.
- The milestone payment is not yet due as dosing has not begun.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1755237/000119312525304067/0001193125-25-304067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1755237/000119312525304067/d48096d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-304067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer